NewsBenzingaGlaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific Biologic Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific Biologic Benzinga 2026.10.08 11:11 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Why Is Applied Digital Stock Surging on Monday?
